South Rampart Pharma's Technology

South Rampart Pharma is developing a new class of small molecule, non-opioid pain medicines. South Rampart Pharma’s (SRP) proprietary compounds have been effective in reducing both pain and fever in preclinical studies without liver and kidney toxicity that are associated with current common over the counter analgesics. SRP compounds are non-opioid, greatly reducing abuse potential.

View Video Transcript

Despite the high prevalence of acute and chronic pain and its toll on society, there has been no innovation in pain medicines in the past six decades. Current treatment options are limited by a narrow therapeutic index – liver toxicity with acetaminophen, kidney toxicity with NSAIDs, and abuse potential with opioids.  Meeting this need head-on, South Rampart Pharma has created SRP-3D (DA), a novel, highly promising new compound that lacks the liver toxicity of acetaminophen while delivering pain relief and fever reduction. This pain relief innovation occurs via the centrally acting mediator, AM404, that works through endocannabinoid receptors.

SRPs’ safety profile is the result of rational drug design focused on avoiding acetaminophen’s liver toxicity. Acetaminophen is metabolized into NAPQI which, in high doses, is hepatotoxic. In contrast, NAPQI is not produced by SRP-3D (DA) metabolism, avoiding this mechanism of toxicity. SRP-3D (DA)’s safety is also evident in the maintenance of hepatic tight junctions which are disrupted with acetaminophen, and the lack of liver toxicity in animal models even at multi-gram per day doses. In addition, SRP-3D (DA) lacks the kidney toxicity seen with NSAID use and, as a non-narcotic, does not have the opioid abuse potential.   Explore the wealth of SRP-3D (DA) data and learn about investment opportunities in SRP’s pain relief innovation by contacting us at

Using extensive knowledge of drug metabolism, molecular modeling and medicinal chemistry, South Rampart Pharma’s synthesized novel compounds have a unique profile as demonstrated in preclinical models:

Demonstrate both pain and fever reduction
Have no liver toxicity seen with high dose treatment
Show no high-dose or alcohol-associated kidney toxicity
Have favorable liver metabolic profile (cytochrome P450)
Are non-opioid suggesting that they will have significantly reduced abuse potential

Additionally, South Rampart Pharma synthesized these new compounds using derivatives of the active metabolite of a first generation ApAP analgesic and all IND-enabling toxicology studies show a favorable safety profile.